Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders

Treatment Adherence Clinical Trial

— CompaSchizo  

Official title:

Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05566015
• Other study ID #: PI2019_843_0021
• Status: Withdrawn
• Phase: N/A
• Start date: September 26, 2022
• Est. completion date: July 1, 2023

Study information

• Verified date: July 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment adherence is defined by the World Health Organisation (WHO) as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment. In patients suffering from psychiatrical diseases, especially in those who are suffering from schizophrenic spectrum disorders, the quality of treatment adherence has to be improved. Indeed, non adherance to anti-psychotic treatment increases the risk of hospitalization, of substance use, violent behaviour and of functionnal and cognitif impairment. Selfcompassion, which involves being touched by and open to one's own suffering and to heal oneself with kindness and without judgement and self-criticism has never beed studied as a possible factor infuencing treatment adherence.

This study aims to evaluate if a link between selfcompassion and treatment adherence exists in patients suffering from schizophrenic spectrum disorders.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients diagnosed with schizophrenia spectrum disorder ( ICD 10 and DSM 5 criteria)

• stabilized (PANNS score under 80)

• aged 18 or above

• In case of tutor or curator, agreement of this person is requiered

• psychiatrist who's following the patient agrees with the study

Exclusion Criteria:

• underage

• non stabilized patient (PANSS score under 80 )

• patient suffering from toxic psychosis

• difficulties to understand french or cognitive impairment which are making it to difficult to answer the different self-administered questionnaires.

Related Conditions & MeSH terms

• Treatment Adherence

Intervention

Other:
• questionnaire
self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (11)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens	CMP de Chambly, CMP de Chantilly, CMP de Clermont de l'Oise, CMP de Creil, CMP de Crepy en Valois, CMP de Montataire, CMP de Pont St Maxence, CMP de Senlis, CMP de st Just en Chaussée, Crysalid center Clermont de l'Oise

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average level of self compassion	The level of self compassion will be assessed with the french version of the Self-compassion scale developped and tested by K.Neff.; Average scores for the Self-Compassion Scale are around 3.0 on the 1-5 Likert scale, a score of 1-2.5 indicates low self-compassion, 2.5-3.5 indicates moderate, and 3.5-5.0 is an indication of high self-compassion	one hour